Gilead profit beats Street expectations on COVID and HIV sales By Reuters
[ad_1] © Reuters. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May 1, 2018. REUTERS/Stephen Lam/File Photo By Michael Erman and Sriparna Roy (Reuters) -Gilead Sciences Inc on Thursday reported a higher-than-expected fourth-quarter profit driven by strong demand for its HIV and cancer drugs, while COVID-19 antiviral Veklury had … Read more